Bluejay diagnostics announces entry into warrant inducement transaction for approximately $3.7 million in gross proceeds

Acton, mass., april 07, 2025 (globe newswire) -- bluejay diagnostics, inc. (nasdaq: bjdx) (“bluejay” or the “company”), a medical technology company developing rapid diagnostics on its symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the company for cash (the “existing warrants”), wherein the investors agreed to exercise the existing warrants to purchase up 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share, resulting in gross proceeds of approximately $3.7 million, before deducting offering fees and other expenses payable by the company.
BJDX Ratings Summary
BJDX Quant Ranking